Clinical Trial Update: An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE [Phase 3]

View source ↗

Summary

An open-label extension of the Phase 3 study of XEN496 (ezogabine) in children with KCNQ2-related developmental and epileptic encephalopathy has been terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kcnq2-related Developmental and Epileptic Encephalopathy

Drugs mentioned

• Ezogabine (ezogabine)

Snippet

Sponsor: Xenon Pharmaceuticals Inc. | Conditions: Epilepsy, Epilepsy in Children | Phase 3 | Status: TERMINATED | Results posted: 2025-02-14